Leaders in Alzheimer’s disease research are opening a new era of aging biology-based drug development.

Credit: AIXabay / CC0 public domain

Effective treatment or prevention of Alzheimer’s disease requires a combination of drugs, and leading experts say they have entered a new era of drug development to provide them.In an editorial published in Alzheimer’s Disease Prevention JournalThe authors state that the two most important factors driving us to success are the wide range of new drug targets under development and the rapid development of biomarkers for Alzheimer’s disease.

“Alzheimer’s disease is a complex disease caused by a combination of factors related to the biology of aging, so it is not surprising that the combination of factors needs to be treated in order to actually affect the disease.” Co-author Dr. Howard said. Philit, co-founder and director of the Alzheimer’s Disease Drug Discovery Foundation (ADDF).

Currently, there are 143 medicines under development to combat Alzheimer’s disease, 119 of which are designed to delay or stop the disease.Amyloid-destroying drugs dominated research not long ago, but today Alzheimer’s disease is on the rise. Clinical trial It targets inflammation more than these proteins. Ongoing trials include metabolism, vascular function, epigenetics ( Gene regulation No changes in DNA sequence) and neuronal cell formation.

Equally important Biomarker, Early diagnosis Recruit the right patients properly and selectively Clinical trials.. The development of biomarkers in the form of blood tests, ophthalmic scans, and even digital technology-based tests helps with early detection and diagnosis. Exactly 10 years ago, the only way to diagnose Alzheimer’s disease was by postmortem autopsy. Today, PET scans of the brain, spinal fluid tests, and even simple blood tests can provide insights into the state of the brain in Alzheimer’s disease.

“Biomarkers ensure that appropriate patients are enrolled in each clinical trial and provide researchers with a means of assessing their response to treatment,” said ADDF Director of Aging and Alzheimer’s Prevention. Dr. Yuko Hara states. “Biomarkers make clinical trials more efficient and rigorous, especially in early-stage trials where it is important to quickly determine if treatment is promising, the cost of clinical trials is most effective. Spent for treatment. “

“As a neuroscientist and geriatrician, I’m more optimistic about my ability to prevent, diagnose, and treat Alzheimer’s disease,” says Dr. Philit. “The ability to diagnose individual causes of Alzheimer’s disease in each patient has improved, and there are well over 100 different drugs in the research pipeline, giving patients a personalized combination approach, as in the case of cancer and cardiovascular. We are closer than ever to offering. Disease. ”

A new generation of treatments based on an understanding of aging biology indicates the potential for Alzheimer’s disease

For more information:
Y. Hara et al, Dawn of a New Era of Alzheimer’s Disease Research and Drug Development, Alzheimer’s Disease Prevention Journal (2022). DOI: 10.14283 / jpad.2022.64

Provided by Alzheimer’s Disease Drug Discovery Foundation

Quote: Leaders of Alzheimer’s disease research herald the dawn of a new era of biology-based drug development for aging (July 6, 2022). -dawn-era.html

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.

Leaders in Alzheimer’s disease research are opening a new era of aging biology-based drug development.

Source link Leaders in Alzheimer’s disease research are opening a new era of aging biology-based drug development.

Show More

Related Articles

Back to top button